| Description | SARS-CoV-2-IN-1 is a potent inhibitor of Mpro(SARS-CoV-2 Mpro, SARS-CoV Mpro and MERS-CoV Mpro with IC50s of 0.67, 0.90 and 0.58 μM, respectively). |
| In vitro | SARS-CoV-2-IN-1 inhibits RNA replication with an EC50 of 1.75 μM in a SARS-CoV replicon. In human Calu3 cells infected with the novel coronavirus, SARS-CoV-2, SARS-CoV-2-IN1(EC50 of 4-5 μM). |
| In vivo | SARS-CoV-2-IN-1 shows the Cmax is 126.2 ng/mL. The mean residence time for SARS-CoV-2-IN-1 is extended to 2.7 hours and the plasma half-life in CD-1 mice is 1.8 hour. |
| molecular weight | 593.67 |
| Molecular formula | C31H39N5O7 |
| CAS | 2412965-59-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Zhang L, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. 2020 Mar 20. pii: eabb3405. |